# Carbidopa for the Treatment of Excessive Blood Pressure Variability

> **NCT02553265** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 22 (actual)

## Conditions studied

- Dysautonomia, Familial
- Baroreflex Failure Syndrome

## Interventions

- **DRUG:** Carbidopa Low-Dose
- **OTHER:** Placebo
- **DRUG:** Carbidopa High-Dose

## Key facts

- **NCT ID:** NCT02553265
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-05-10
- **Final completion:** 2019-05-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553265, "Carbidopa for the Treatment of Excessive Blood Pressure Variability". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02553265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*